Enochian Biosciences Inc. (ENOB) stock gained 35.71% in the extending trading session on Wednesday, March 24, 2021, after the company made a special announcement about achieving important results about the recurrent glioblastoma
On March 24, 2021, the Enochian Biosciences and SRI announced achieving complete remission for 15 months, in a 36years old patient with recurrent glioblastoma. important findings were published today, in the peer-reviewed American Journal of Case.
It is very rare, in fact, impossible to achieve complete remission for this highly aggressive and deadly form of brain cancer.
The patient was treated with natural killer (NK) and dendritic cells (DC) from a relative who had a partial genetic mismatch. The DCs were loaded with a component of cytomegalovirus that is known to be present in more than 90 percent of glioblastomas.
Participation in the investors’ conference
Enochian Biosciences participated virtually in the H.C. Wainwright Global Life Sciences Conference which held on Tuesday, March 9, 2021. The company was presented by Executive Vice Chairman Dr. Mark Dybul who provided an overview of the company’s progress, including its innovative HIV, Hepatitis B, and Oncology platforms.
Enochian BioSciences was founded in 2011 and based in Los Angeles ENOB is a gene-modified cell therapy company with a clear mission of developing definitive cures and provide effective prevention for infectious disease and cancer. the company is lead by Dr. Mark Dybul who is the Executive Vice Chairman of the company. He has thirty years of working experience in HIV and public health as a clinician, scientist, teacher, and administrator.
Conclusion: The recent results about achieving complete remission with recurrent glioblastoma can bring a revolution for cancer patients. The ENOB stock can further rise significantly in the coming days.